46
Participants
Start Date
September 7, 2017
Primary Completion Date
December 28, 2020
Study Completion Date
December 28, 2020
Emerfetamab
Administered by intravenous (IV) infusion.
The Alfred Hospital, Melbourne
The Royal Melbourne Hospital, Parkville
University of Alabama at Birmingham, Birmingham
University of Texas MD Anderson Cancer Center, Houston
Klinikum der Ludwig Maximilians Univeritaet, München
City of Hope National Medical Center, Duarte
University of Washington, Seattle
Lead Sponsor
Amgen
INDUSTRY